Atopic Dermatitis / Atopic Eczema – Landscape & Forecast – Disease Landscape & Forecast

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch. Topical therapies are often effective for mild disease but have suboptimal safety, tolerability, and compliance. More-effective therapies for topical-refractory patients and, more generally, moderate to severe AD patients are a key focus of drug development driving the AD market. This upheaval began with the 2017 launches of Sanofi / Regeneron’s injectable biologic Dupixent (dupilumab) and Pfizer’s nonsteroidal topical cream Eucrisa (crisaborole). Since then, eight agents have been approved: three oral JAK inhibitors (Eli Lilly’s Olumiant [baricitinib], AbbVie’s Rinvoq [upadacitinib], and Pfizer’s Cibinqo [abrocitinib]); three nonsteroidal topical agents (Japan Tobacco’s Corectim [delgocitinib], Incyte’s Opzelura [ruxolitinib], and Otsuka and Acrotech Biopharma’s Moizerto [difamilast]); one IL-31 inhibitor (Galderma / Chugai / Maruho’s Mitchga [nemolizumab]), and one targeted biologic (LEO Pharma’s Adbry / Adtralza [tralokinumab]). This report provides a comprehensive analysis of AD patient populations, current disease management, unmet needs, and the potential of current and emerging drugs.

QUESTIONS ANSWERED

• What are the sizes of the mild, moderate, and severe AD subpopulations, and how will they change by 2031? How well are they served by current therapies?
• How have Eucrisa and Dupixent been incorporated into the AD treatment algorithm? What market niches are newly launched oral JAK inhibitors (e.g., Cibinqo, Rinvoq, Olumiant), topicals (e.g., Corectim, Opzelura, Moizerto), and other biologics (e.g., Adbry, Mitchga) beginning to occupy?
• What therapies are in development for AD? Of these therapies, which are best positioned to achieve commercial success?
• What are the greatest unmet needs in the treatment of AD, and to what degree will therapies in the pipeline address these needs?

Content highlights:

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 15 country-specific interviews with thought leaders. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed and drug-treated prevalence of atopic dermatitis by country; 12-month total and diagnosed prevalence of atopic dermatitis by severity.

Emerging therapies: Phase III / PR / Approved: ~15 drugs; Phase I/II: > 20 drugs; coverage of select early-phase products.

Forecast: 10-year, annualized, drug-level sales and patient share of key atopic dermatitis therapies through 2031, segmented by brands / generics, disease severity, and pediatric / adult subpopulations.

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.